This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Halabi, S. Articles by Small, E. J. Search for Related Content PubMed Articles by Halabi, S. Articles by Small, E. J. Related Articles Related Correspondence Social Bookmarking                            What's this?

Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer

Susan Halabi, Nicholas J. Vogelzang, Alice B. Kornblith, San-San Ou, Philip W. Kantoff, Nancy A. Dawson, Eric J. Small

From the Department of Biostatistics and Bioinformatics, Duke University, and Cancer and Leukemia Group B Statistical Center, Durham, NC; Dana Farber Cancer Institute, Boston, MA; Georgetown University, Washington, DC; Nevada Cancer Institute, Las Vegas, NV; and University of California at San Francisco, San Francisco, CA

Corresponding author: Susan Halabi, PhD, Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Rd, Durham, NC 27705; e-mail: susan.halabi{at}duke.edu

Purpose Pain from castration-refractory prostate cancer (CRPC) bone metastases is a common event. Although it is assumed that pain represents an adverse prognostic factor, this variable has not been extensively evaluated. The objective of this study was to determine whether men with CRPC who had higher pain interference scores at baseline had worse clinical outcomes compared with men who had lower pain scores.

Patients and Methods Data from three randomized phase III multicenter trials conducted by the Cancer and Leukemia Group B from 1992 to 1998 were combined. Eligible patients had progressive CRPC adenocarcinoma of the prostate, an Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate hematologic, renal, and hepatic functions. Seven items from the Brief Pain Inventory were used to assess the impact of pain on a range of daily activities and quality of life, each rated on a scale from 0 to 10.

Results In 599 men, the median pain interference scores was 17 (interquartile range, 4 to 34), and 38% of the men had opioid analgesic use at baseline. There was a statistically significant association between pain interference scores and risk of death. The median survival times were 17.6 months (95% CI, 16.1 to 19.1 months) and 10.2 months (95% CI, 8.6 to 11.3 months; P < .001) in men with low (< 17) and high ( 17) pain scores, respectively. Pain was inversely associated with likelihood of prostate-specific antigen decline, objective response, and time to bone progression.

Conclusion This analysis demonstrates that pain is a statistically significant predictor of overall survival in men with metastatic CRPC. These results need to be validated prospectively in future phase III trials.

Supported in part by grants from the United States Department of Defense (Grants No. DAMD 17-03-1-0112 and W81XWH-06-1-0032) and the National Cancer Institute (Grant No. CA 36601).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Predication of Cancer Patients’ Survival by Pain Interference Items Is Not the Same As Evidence That Pain Intensity Is a Survival Predictor
  Pål Klepstad and Stein Kaasa
  JCO 2008 26: 4215-4216 [Full Text]
• Predication of Cancer Patients’ Survival by Pain Interference Items Is Not the Same As Evidence That Pain Intensity Is a Survival Predictor
  Pål Klepstad and Stein Kaasa
  JCO 2008 26: 4215-4216 [Full Text]

This article has been cited by other articles:

				E. Basch, X. Jia, G. Heller, A. Barz, L. Sit, M. Fruscione, M. Appawu, A. Iasonos, T. Atkinson, S. Goldfarb, et al. Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes J Natl Cancer Inst, November 17, 2009; (2009) djp386v1. [Abstract] [Full Text] [PDF]

				A. J. Armstrong and P. G. Febbo Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature Oncologist, August 1, 2009; 14(8): 816 - 827. [Abstract] [Full Text] [PDF]

				S. Halabi, N. J. Vogelzang, S.-S. Ou, K. Owzar, L. Archer, and E. J. Small Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer J. Clin. Oncol., June 10, 2009; 27(17): 2766 - 2771. [Abstract] [Full Text] [PDF]

				P. Klepstad and S. Kaasa Predication of Cancer Patients' Survival by Pain Interference Items Is Not the Same As Evidence That Pain Intensity Is a Survival Predictor J. Clin. Oncol., September 1, 2008; 26(25): 4215 - 4216. [Full Text] [PDF]

				S. Halabi, N. J. Vogelzang, A. B. Kornblith, S.-S. Ou, P. W. Kantoff, N. A. Dawson, and E. J. Small In Reply J. Clin. Oncol., September 1, 2008; 26(25): 4216 - 4217. [Full Text] [PDF]